Loomis, Sayles & Company
TARS icon

Loomis, Sayles & Company’s Tarsus Pharmaceuticals TARS Stock Holding History

Loomis, Sayles & Company’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24M Sell
380,684
-27,152
-7% -$1.73M 0.03% 225
2026
Q1 		$28.6M Sell
407,836
-34,037
-8% -$2.38M 0.04% 175
2025
Q4 		$36.2M Buy
441,873
+51,972
+13% +$3.88M 0.04% 151
2025
Q3 		$23.2M Buy
+389,901
New +$19.2M 0.03% 216

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Loomis, Sayles & Company's TARS Position: Q2 2026 in Review

Loomis, Sayles & Company reduced its Tarsus Pharmaceuticals (TARS) stake by 6.7% in Q2 2026, selling an estimated $1.73M and leaving 380,684 shares worth $24M. The position accounts for 0.03% of the portfolio, ranked #225.

Loomis, Sayles & Company first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. The position peaked at $36.2M in Q4 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Loomis, Sayles & Company held 380,684 shares of Tarsus Pharmaceuticals worth $24M as of Q2 2026.
  • Loomis, Sayles & Company sold 27,152 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.73M.
  • Tarsus Pharmaceuticals made up 0.03% of Loomis, Sayles & Company's portfolio in Q2 2026, its #225 holding.
  • Loomis, Sayles & Company first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Loomis, Sayles & Company's Tarsus Pharmaceuticals position peaked at $36.2M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.